Alphamab Oncology
HKEX:9966
Alphamab Oncology
HKEX:9966
Price:
9.15
HKD
0.33%
Market Cap:
HK$8.9B
Balance Sheet
Balance Sheet Decomposition
Alphamab Oncology
Alphamab Oncology
Balance Sheet Decomposition is not available for
Alphamab Oncology
Alphamab Oncology
Balance Sheet
Alphamab Oncology
Alphamab Oncology
Currency: CNY
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
0
|
634
|
1 868
|
185
|
803
|
1 069
|
1 086
|
1 112
|
|
| Cash |
0
|
95
|
54
|
44
|
271
|
117
|
177
|
502
|
|
| Cash Equivalents |
0
|
538
|
1 814
|
141
|
533
|
953
|
909
|
610
|
|
| Short-Term Investments |
1
|
0
|
515
|
1 879
|
1 182
|
281
|
321
|
459
|
|
| Total Receivables |
7
|
15
|
36
|
85
|
68
|
80
|
73
|
58
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
8
|
15
|
7
|
17
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
60
|
64
|
65
|
42
|
|
| Inventory |
3
|
7
|
26
|
44
|
58
|
65
|
79
|
82
|
|
| Other Current Assets |
0
|
0
|
0
|
6
|
6
|
0
|
0
|
0
|
|
| Total Current Assets |
11
|
656
|
2 444
|
2 199
|
2 117
|
1 495
|
1 559
|
1 711
|
|
| PP&E Net |
35
|
160
|
379
|
406
|
545
|
621
|
578
|
529
|
|
| PP&E Gross |
35
|
160
|
379
|
406
|
545
|
621
|
578
|
529
|
|
| Accumulated Depreciation |
1
|
8
|
2
|
21
|
50
|
90
|
145
|
209
|
|
| Note Receivable |
0
|
11
|
31
|
34
|
44
|
2
|
1
|
2
|
|
| Total Assets |
47
N/A
|
827
+1 675%
|
2 855
+245%
|
2 640
-8%
|
2 705
+2%
|
2 118
-22%
|
2 137
+1%
|
2 242
+5%
|
|
| Liabilities | |||||||||
| Accounts Payable |
2
|
1
|
7
|
2
|
28
|
12
|
32
|
42
|
|
| Accrued Liabilities |
3
|
18
|
64
|
78
|
109
|
141
|
120
|
119
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
11
|
42
|
198
|
464
|
190
|
80
|
55
|
|
| Other Current Liabilities |
5
|
53
|
88
|
52
|
36
|
42
|
35
|
38
|
|
| Total Current Liabilities |
10
|
83
|
201
|
330
|
637
|
385
|
267
|
254
|
|
| Long-Term Debt |
0
|
1 001
|
211
|
25
|
173
|
155
|
177
|
131
|
|
| Minority Interest |
13
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
10
|
10
|
17
|
12
|
24
|
20
|
22
|
25
|
|
| Total Liabilities |
33
N/A
|
1 094
+3 199%
|
429
-61%
|
366
-15%
|
835
+128%
|
560
-33%
|
465
-17%
|
410
-12%
|
|
| Equity | |||||||||
| Common Stock |
20
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
7
|
267
|
1 008
|
1 439
|
1 847
|
2 168
|
2 380
|
2 213
|
|
| Additional Paid In Capital |
0
|
0
|
3 434
|
3 713
|
3 717
|
3 726
|
4 053
|
4 055
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
|
| Other Equity |
0
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
|
| Total Equity |
13
N/A
|
267
N/A
|
2 426
N/A
|
2 273
-6%
|
1 870
-18%
|
1 558
-17%
|
1 672
+7%
|
1 832
+10%
|
|
| Total Liabilities & Equity |
47
N/A
|
827
+1 675%
|
2 855
+245%
|
2 640
-8%
|
2 705
+2%
|
2 118
-22%
|
2 137
+1%
|
2 242
+5%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
718
|
718
|
897
|
935
|
937
|
940
|
965
|
962
|
|
Switch to:
Switch to:
See Also
Discover More
